For following the competition: what moved in each program, several studies read as one move.
- ODM-216
- Pan-TEAD Inhibitor ODM-212
- tasipimidine
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Orion Corporation, Orion Pharma to watchlistEvery Monday by email · turn it off any timePro · free during the beta